The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial
Burneikaitė G, Shkolnik E, Puronaitė R, Zuozienė G, Petrauskienė B, Misonis N, Kazėnaitė E, Laucevičius A, Smih F, Rouet P, Čelutkienė J. The association of catestatin and endocan with the effects of cardiac shock wave therapy: Biomarker sub-study of the randomized, sham procedure-controlled trial. Frontiers In Cardiovascular Medicine 2023, 10: 1004574. PMID: 36910537, PMCID: PMC9996196, DOI: 10.3389/fcvm.2023.1004574.Peer-Reviewed Original ResearchCardiac shock wave therapyEndocan levelsShock wave therapyMyocardial perfusionContractile functionCoronary collateral developmentWhole study populationWall motion scorePotential predictive valueAssociation of increasesAvailable ELISA kitsCatestatin concentrationsDobutamine echocardiographyStable anginaEndocan concentrationsRevascularization proceduresCatestatin levelsMyocardial scintigraphyCollateral developmentWave therapyInclusion criteriaMotion scoreStudy populationBlood samplesPredictive value